Liaoning Chengda Biotechnology Co (688739.SS) Stock Price
Liaoning Chengda Biotechnology Co Price
Over the last 13 years Liaoning Chengda Biotechnology Co grew revenue by 2.7% annually, reaching 1.39 B CNY. Earnings per share have declined at 10.7% per year over the last 13 years. For Liaoning Chengda Biotechnology Co, the net margin of 9.5% is down versus 42.7% a few years ago. At today's price the dividend yield works out to roughly 3.98%. The payout ratio is around 253% of earnings. The consensus 12-month price target for Liaoning Chengda Biotechnology Co is 40.80 CNY, about 102.8% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Liaoning Chengda Biotechnology Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Liaoning Chengda Biotechnology Co business model & stock analysis
Frequently asked questions about Liaoning Chengda Biotechnology Co
Analysts currently set an average price target of 40.80 CNY for the Liaoning Chengda Biotechnology Co stock (median: 40.80 CNY), implying +98.9 % versus the latest price. The consensus is based on 5 analyst ratings.
Liaoning Chengda Biotechnology Co Analyst Price Targets 2026
5 analysts currently rate the Liaoning Chengda Biotechnology Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Liaoning Chengda Biotechnology Co to generate revenue of 1.28 B CNY and earnings per share of 0.45 CNY.
Liaoning Chengda Biotechnology Co Analyst Price Targets 2026
Converted at the current exchange rate, the Liaoning Chengda Biotechnology Co share trades at 2.69 EUR (20.12 CNY).
The expected revenue of Liaoning Chengda Biotechnology Co is 1.28 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Liaoning Chengda Biotechnology Co is 185.87 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Liaoning Chengda Biotechnology Co is currently 45.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Liaoning Chengda Biotechnology Co stock.
The price-to-sales ratio (P/S) of Liaoning Chengda Biotechnology Co is currently 6.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Liaoning Chengda Biotechnology Co stock.
The Eulerpool Quality Score for Liaoning Chengda Biotechnology Co is 2/10.
The ISIN of Liaoning Chengda Biotechnology Co is CNE100004ZP2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Liaoning Chengda Biotechnology Co is 688739.SS. The ticker symbol is used to trade Liaoning Chengda Biotechnology Co shares on the stock exchange.
Liaoning Chengda Biotechnology Co stock
Liaoning Chengda Biotechnology Co Peer Group
Liaoning Chengda Biotechnology Co FIGI
All fundamentals and in-depth analysis of Liaoning Chengda Biotechnology Co
Our stock analysis for Liaoning Chengda Biotechnology Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Liaoning Chengda Biotechnology Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.